HERTFORDSHIRE, England and PITTSBURGH, Dec. 1, 2016 /PRNewswire/ -- Today, Mylan N.V. (NASDAQ, TASE: MYL) joins people worldwide in recognizing World AIDS Day. Observed every Dec. 1, the occasion represents an opportunity to support people living with HIV/AIDS and to remember the approximately 35 million who have died from AIDS-related illnesses since the epidemic began.
Mylan always has been committed to providing people with access to more affordable medicines, and years ago made a commitment to stem the tide of HIV/AIDS by bringing to bear its ability to innovate, commitment to quality and growing manufacturing scale to help the people who most need it, no matter where they are or who they are. "At Mylan, we view every day of every year as an opportunity to stem the disease's tide," commented Mylan CEO Heather Bresch. "Mylan's ARV products now are used by approximately half of everyone on the planet who is receiving treatment for HIV/AIDS. So it's important that we continue to invest and to leverage the millions of dollars we already have invested over the past several years to scale up our portfolio and ARV manufacturing capacities." Mylan is one of the world's leading providers of HIV/AIDS medicines and strives to meet global demand with a reliable supply of affordable medications. Its portfolio currently contains 16 active pharmaceutical ingredients (API) and 50 finished dosage forms. Mylan continues to invest in R&D and operations to keep pace and stay ahead in providing the comprehensive basket of vertically integrated and affordable quality drug products for the future. "Mylan has a long tradition of innovation, and we're not standing still," said Mylan President Rajiv Malik. "We have more than 3,000 scientists worldwide, many of them dedicated to our ARV franchise, working to develop innovative solutions to satisfy unmet needs. Their skill and dedication allowed us to submit an application in March 2016 to the U.S. Food and Drug Administration for a reduced-dose version of the world's most commonly used ARV combination drug, Tenofovir Disoproxil Fumarate + Lamivudine + Efavirenz." Mylan's version, which uses one-third less Efavirenz, is formulated to be as effective as the original version. If approved, the company believes it will improve the side effect profile and also will save payers money by requiring less API in each tablet, a meaningful change for a product now used by more than 5.5 million people each year.